Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Conversation
The Conversation
Sarah Pitt, Principal Lecturer, Microbiology and Biomedical Science Practice, Fellow of the Institute of Biomedical Science, University of Brighton

RSV: we finally have a vaccine for this deadly virus

The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration. The vaccine, named Arexvy, will be given to people 60 years and older.

The European Medicines Agency is recommending the use of this vaccine, with a final decision likely to be made in July 2023. The UK drugs regulator is also considering the evidence.

RSV is quite closely related to measles and mumps viruses, but unlike those two, it mostly causes symptoms similar to a bad cold. It is spread through coughing and sneezing and it can hang around on surfaces for several hours. It is found all over the world, with most cases occurring in winter.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.